2-[(1S,2RS)-1-ethyl-2-hydroxy-3,3-dimethylbutylamino]-9-isopropyl-6-[(pyridin-3-ylmethyl)-amino]purine | 660822-29-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-[(1S,2RS)-1-ethyl-2-hydroxy-3,3-dimethylbutylamino]-9-isopropyl-6-[(pyridin-3-ylmethyl)-amino]purine
• 英文别名: (3RS,4S)-4-{9-isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2,2-dimethyl-hexan-3-ol；(3RS,4S)-4-{9-isopropyl-6-[(pyridin-3-ylmethyl)amino]-9H-purin-2-ylamino}-2,2-dimethylhexan-3-ol；(4S)-2,2-dimethyl-4-[[9-propan-2-yl-6-(pyridin-3-ylmethylamino)purin-2-yl]amino]hexan-3-ol
• CAS: 660822-29-7
• 化学式: C₂₂H₃₃N₇O
• 分子量: 411.55
• InChiKey: XHPNYYOUZWOWNT-ATNAJCNCSA-N

物化性质

• 沸点：
  615.5±65.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  30
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  101
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-氟-6-氯嘌呤 在 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 2,4-滴二甲胺盐 、 二甲基亚砜 、 正丁醇 为溶剂， 反应 139.5h， 生成 2-[(1S,2RS)-1-ethyl-2-hydroxy-3,3-dimethylbutylamino]-9-isopropyl-6-[(pyridin-3-ylmethyl)-amino]purine
  参考文献：
  名称：

  Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors

  摘要：

  The cyclin-dependent kinase (CDK) inhibitor seliciclib (1, CYC202) is in phase II clinical development for the treatment of cancer. Here we describe the synthesis of novel purines with greater solubility, lower metabolic clearance, and enhanced potency versus CDKs. These compounds exhibit novel selectivity profiles versus CDK isoforms. Compound alpha SbR-21 inhibits CDK2/cyclin E with IC(50) = 30 nM, CDK7-cyclin H with IC(50) = 1.3 mu M, and CDK9-cyclinT with IC(50) = 0.11 mu M; it (CCT68127) inhibits growth of HCT116 colon cancer cells in vitro with GI(50) = 0.7 mu M; and shows antitumour activity when dosed p.o. at 50 mg/kg to mice bearing HCT116 solid human tumour xenografts. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.08.051

文献信息

• NEW PURINE DERIVATIVES
  申请人：FISCHER Peter Martin

  公开号：US20090325983A1

  公开（公告）日：2009-12-31

  The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R 1 and R 2 is methyl, ethyl or isopropyl, and the other is H; R 3 and R 4 are each independently H, branched or unbranched C 1 -C 6 alkyl, or aryl, and wherein at least one of R 3 and R 4 is other than H; R 5 is a branched or unbranched C 1 -C 5 alkyl group or a C 1 -C 6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R 6 , R 7 , R 8 and R 9 are each independently H, halogen, NO 2 , OH, OMe, CN, NH 2 , COOH, CONH 2 , or SO 2 NH 2 . A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.

  本发明涉及公式1的化合物或其药学上可接受的盐，其中R1和R2中的一个是甲基、乙基或异丙基，另一个是氢；R3和R4各自独立地是氢、支链或非支链的C1-C6烷基或芳基，且其中至少一个不是氢；R5是支链或非支链的C1-C5烷基或C1-C6环烷基，每个基团都可以选择地用一个或多个OH基团进行取代；R6、R7、R8和R9各自独立地是氢、卤素、NO2、OH、OMe、CN、NH2、COOH、CONH2或SO2NH2。本发明的另一个方面涉及包含上述公式1化合物的制药组合物，以及在治疗增殖性疾病、病毒性疾病、中风、脱发、中枢神经系统疾病、神经退行性疾病或糖尿病中使用上述化合物的用途。
• Purine derivatives
  申请人：Cyclacel Limited

  公开号：US07582642B2

  公开（公告）日：2009-09-01

  The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.

  本发明涉及公式1的化合物或其药学上可接受的盐，其中R1和R2中的一个是甲基、乙基或异丙基，另一个是氢；R3和R4各自独立地是氢、支链或非支链的C1-C6烷基或芳基，并且至少有一个R3和R4不是氢；R5是支链或非支链的C1-C5烷基或C1-C6环烷基，每个基团可以选择性地取代一个或多个OH基团；R6、R7、R8和R9各自独立地是氢、卤素、NO2、OH、OMe、CN、NH2、COOH、CONH2或SO2NH2。 本发明的另一个方面涉及包含公式1化合物的药物组合物，并且使用所述化合物治疗增殖性疾病、病毒性疾病、中风、脱发、中枢神经系统疾病、神经退行性疾病或糖尿病。
• PROCESS FOR THE PREPARATION OF 2,6,9-TRISUBSTITUTED PURINES
  申请人：Cyclacel Limited

  公开号：EP2010533A2

  公开（公告）日：2009-01-07
• JP2006506341A
  申请人：——

  公开号：JP2006506341A

  公开（公告）日：2006-02-23
• 新しいプリン誘導体
  申请人：サイクラセル・リミテッド

  公开号：JP4723858B2

  公开（公告）日：2006-02-23